Literature DB >> 30745320

The Role of ACKR3 in Breast, Lung, and Brain Cancer.

Maria Neves1, Amos Fumagalli1, Jelle van den Bor1, Philippe Marin1, Martine J Smit1, Federico Mayor2.   

Abstract

Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2019        PMID： 30745320     DOI： 10.1124/mol.118.115279

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN： 0026-895X            Impact factor:   4.436


  7 in total

1.  Modulation of CXCR4-Mediated Gi1 Activation by EGF Receptor and GRK2.

Authors:  Maria Neves; Cristina Perpiñá-Viciano; Petronila Penela; Carsten Hoffmann; Federico Mayor
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-27

2.  Differential Involvement of ACKR3 C-Tail in β-Arrestin Recruitment, Trafficking and Internalization.

Authors:  Aurélien Zarca; Claudia Perez; Jelle van den Bor; Jan Paul Bebelman; Joyce Heuninck; Rianna J F de Jonker; Thierry Durroux; Henry F Vischer; Marco Siderius; Martine J Smit
Journal:  Cells       Date:  2021-03-11       Impact factor: 6.600

Review 3.  CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.

Authors:  Sara Santagata; Caterina Ieranò; Anna Maria Trotta; Anna Capiluongo; Federica Auletta; Giuseppe Guardascione; Stefania Scala
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

4.  Analysis of Clinical Characteristics, Treatment, and Prognostic Factors of 106 Breast Cancer Patients With Solitary Pulmonary Nodules.

Authors:  Lihong He; Xiaorui Wang; Xiaodong Liu; Yongsheng Jia; Weipeng Zhao; Xiaochen Jia; Yuehong Zhu; Wenjing Meng; Zhongsheng Tong
Journal:  Front Surg       Date:  2022-02-15

5.  CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.

Authors:  Yang Li; Shukun Han; Baokang Wu; Chongli Zhong; Yu Shi; Chao Lv; Lei Fu; Yizhou Zhang; Qi Lang; Zhiyun Liang; Yang Yu; Yu Tian
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

6.  Crosstalk between CXCR4/ACKR3 and EGFR Signaling in Breast Cancer Cells.

Authors:  Maria Neves; Viviana Marolda; Federico Mayor; Petronila Penela
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

7.  Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells.

Authors:  Sha Zhu; Zhixue Min; Xianli Qiao; Shengxian Chen; Jian Yang; Xiao Zhang; Xigang Liu; Weijie Ran; Renguang Lv; Ying Lin; Jin Wang
Journal:  Aging (Albany NY)       Date:  2019-12-29       Impact factor: 5.682
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.